Antibodies against oxidized low-density lipoproteins in systemic sclerosis

Rheumatology

Volumn 40, Issue 4, 2001, Pages 401-405

  Herrick, A L ^a   Illingworth, K J ^a   Hollis, S ^b   Gomez Zumaquero, J M ^c   Tinahones, F J ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Anti oxidized LDL antibodies; Lipoproteins; Oxidant stress; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BLOOD VESSEL INJURY; CALCULATION; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENDER; HUMAN; LONGITUDINAL STUDY; MALE; MEASUREMENT; OPTICAL DENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; SCLERODERMA; SMOKING; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0035031890     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pathogenesis of systemic sclerosis: A vascular hypothesis
2. A radical proposal for the pathogenesis of scleroderma
3. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration white finger
4. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon
5. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon
6. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis
7. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis
8. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma
9. Elevated plasma superoxide dismutase activity in patients with systemic sclerosis
10. Role of oxidized low density lipoprotein in atherogenesis
11. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis
12. Autoantibody against oxidised LDL and progression of carotid atherosclerosis
13. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
14. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome
15. Lack of cross-reaction between antibodies to beta2-glyco-protein-1 and oxidized low-density lipoprotein in patients with antiphospholipid syndrome
16. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM
17. Oxidative stress in systemic sclerosis
18. Reliability of skin involvement measures in scleroderma
19. Continuous monitoring of in vitro oxidation of human low density lipoprotein
20. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man
21. Dietary intake and nutritional status in patients with systemic sclerosis
22. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis
23. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia
24. Laser Doppler imaging-a new technique for quantifying microcirculatory flow in patients with primary Raynaud's phenomenon and systemic sclerosis
25. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
26. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis
27. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis